Top Palo Alto, CA Pharmaceutical Startups (34)
Drug Hunter™ is an essential subscription service for R&D-focused organizations turning molecules into medicines. Every day, drug discovery strategies, tactics, challenges and solutions are disclosed, but the knowledge is fragmented across journals, conferences, patents, databases, news, company reports, filings and endless other sources, making it challenging to find and apply. Drug Hunter’s experts keep you current by connecting the dots, distilling industry...
ImmunEdge is a biopharmaceutical company committed to developing novel therapeutics for patients with serious or life-threatening diseases. With a highly experienced team of experts in immunology and drug development, we are pioneering innovative approaches to target and modulate key molecular pathways that regulate the immune response.
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating...
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and...
Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by...
We use data to understand what specialty drugs do at the individual, not population level. Our specialty drug management product, VIVIO Precision Care™ fixes big unsolved healthcare problems: expensive drug therapies that don’t work; lack of real-world effectiveness; doctors prescribing based on opinion and experience instead of data; the arbitrary line between pharmacy drug and medical benefit; and, egregious supply...
Claritas Rx is a digital health venture that brings clarity to the challenges of specialty biopharmaceutical products in the marketplace. In today’s highly complex specialty networks, our mission is to illuminate the patient experience beyond the clinical trial. Claritas Rx leverages a proprietary technology platform and deep manufacturer expertise to automate and integrate channel, commercial, and clinical data and help...
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's...
Pulse Biosciences is the inventor and sole proprietor of Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. We are committed to health innovation that has the potential to improve and extend the lives of patients. Our proprietary Nanosecond Pulsed Field Ablation technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The people at Pulse Biosciences are...
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of...
Adimab is the most successful antibody discovery company in the industry, with 600+ discovery campaigns and 80+ clinical programs created with more than 130 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all...
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than...
Pliant Therapeutics is a late-stage clinical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates aimed at halting or even reversing fibrotic diseases and address the unmet needs of many patients. Pliant’s...
SeqMatic is a CRO Laboratory that provides superior end-to-end NGS, Multi-omics and histopathology workflow solutions including DNA, RNA, Single Cell, Epigenomics, Spatial, Histology & Bioinformatics. All work performed in Fremont, CA. Founded in 2012 by former Illumina R&D scientists. Certified by Illumina, 10x Genomics and Parse Biosciences. CLIA/CAP accredited laboratory with robust Quality Management Systems. Our work has been cited...
iota Biosciences, a wholly-owned subsidiary of Astellas Pharma US, is a medical device company working to develop pioneering bioelectronics to advance the treatment and management of disease. Founded in 2017 to build on the award-winning ultrasound technology invented at the University of California, Berkeley, iota Biosciences is committed to improving human life and bringing our groundbreaking approaches to the patients...
At BioNex Solutions, we develop instrumentation and integrated systems that solve the most demanding applications in biopharmaceutical, biotech, and academic research. Our hardware and software philosophy is to design single-purpose, high performance modules, and integrate them to produce the desired functionality. Rather than push a single, generalized product that tries to meet the needs of every customer, we prefer to...
WithMe Health is an innovative pharmacy benefits company that works directly with employers and health benefit vendors to provide you and your family with easy to understand pharmacy benefits. WithMe provides personalized medication guidance, with hands-on support from Medication Guides (expert pharmacists and pharmacy technicians) as well as an easy-to-use mobile app to help you manage your medications and see...
We are a biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug...
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). Our pipeline also includes additional investigational products and lead...
